Non-healthcare costs of hepatitis C: a systematic review

Pascual-Argente, Natàlia; Puig‐Junoy, Jaume; Llagostera-Punzano, Anna

doi:10.1080/17474124.2017.1373016

Cited by 14 publications

(10 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This worrisome situation puts at risk the achievement of the WHO HCV elimination goals in the EU and entails a high burden of disease and financial consequences for the EU population as a whole (e.g. not only direct medical costs, often with highly expensive procedures such as liver transplantation, but also indirect costs as those due to decreased work productivity) [34–38]. Health authorities at the EU and country levels should therefore take measures to overcome the challenges of eliminating HCV among PWID in a way that preserves human rights and mitigates health inequalities [39].…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C services at harm reduction centres in the European Union: a 28-country survey

et al. 2019

View full text Add to dashboard Cite

BackgroundIn the context of the WHO’s 2016 Viral Hepatitis Strategy and the introduction of treatment that can cure more than 95% of cases with hepatitis C virus (HCV) infection, the European Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT) undertook a study in the member states of the European Union (EU). It aimed to determine service providers’ understanding of the current services in their respective countries and the barriers experienced by PWID in accessing HCV testing, care and treatment services in their country.MethodsIn 2017, 38 purposively selected harm reduction service providers completed a 26-item English-language online survey addressing the availability, accessibility and funding of HCV services at harm reduction centres. HCV-related data and reported findings were extracted by country or by responding organization.ResultsResponses were received from all EU member states. Respondents from 23 countries reported that HCV tests are offered by harm reduction services in their countries, and eight countries reported that addiction specialists in their countries are able to prescribe HCV therapy. Almost half of the respondents (45%) said that their respective organizations had established referral systems with centres providing HCV treatment.ConclusionsNot all EU member states have harm reduction services that provide HCV tests, and many do not have established referral systems with treatment providers. Moreover, the inability of addiction specialists to prescribe HCV treatment points to missed opportunities to make treatment more accessible. Further, discrepancies were noted between the available HCV services and stakeholders’ knowledge about their availability.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis C services at harm reduction centres in the European Union: a 28-country survey

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The most frequent study type found in this review utilized a retrospective cohort design (77%, 24/31), followed by crosssectional (16%, 5/31). There were two previously published systematic reviews (6%) that met the inclusion criteria [28,45]. In terms of costing method, Sum Diagnosis Specific was the most common (39%, 12/31), with Regression as the next most common (32%, 10/31).…”

Section: Methodological Heterogeneitymentioning

confidence: 99%

“…Authors evaluated each study for risk of bias specific to the reported costs associated with HCV disease and rated the majority of studies either high risk (15/31, 48%) or moderate risk (13/31, 42%). Only three studies (3/31, 10%) were given low risk scores, two of which were systematic reviews that included multiple country estimates [23,28,45]. Source of study funding was discussed as a possible variable to consider for bias, but the authors preferred to report funding separately for the reader to consider rather than make any judgments based on funder (Table 2).…”

Section: Risk Of Bias For Cost Estimatesmentioning

confidence: 99%

Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review

2020

View full text Add to dashboard Cite

Background The introduction of direct-acting antivirals (DAAs) represents a potential clinical cure for hepatitis C virus (HCV) infection. Identification of costs associated with different stages of untreated disease through cost-of-illness (COI) evaluation helps inform policy decisions and cost-effectiveness analyses (CEAs). This study's objective was to review published real-world costs for patients with HCV to estimate the COI across different stages of disease progression. Methods A literature search of EMBASE, Scopus, and PubMed from January 1, 2010 to August 31, 2019 was conducted to identify real-world evidence related to HCV. Data extraction included citation details, population, study type, costing method used, currency and inflation adjustments, and disease-specific costs. Standardized costing method categories (sum all medical, sum diagnosis specific, matching, regression, other incremental, and other total) were assigned. The risk of bias was assessed at the outcome level for influence on costs attributable to HCV. Results The search strategy identified 278 studies, with 31 included in the final review after inclusion and exclusion criteria were applied. Retrospective cohorts (77%) and cross-sectional analyses (16%) were most frequently encountered. Sum Diagnosis Specific was the most common costing method (39%), followed by Regression (32%). Of the 31 studies analyzed, 35% included costs that would be included in a societal model. Costs were identified for various stages and complications related to HCV disease progression. Several studies included were determined to have a high (48%) or moderate risk (42%) of bias related to COI estimates. Conclusion Cost estimates for formal, informal, and non-health care services were identified in this review, but several challenges still exist in fully quantifying HCV burden. Future modeling studies including cost inputs should critically evaluate the risk of bias based on costing methods and data sources.

show abstract

“…La edad como factor de riesgo de infección por el VHC El cribado de una enfermedad determinada es un «servicio» de salud pública en el que los miembros de una población definida son invitados a someterse a preguntas o pruebas para identificar a los individuos con mayor probabilidad de obtener un beneficio que un perjuicio -causado por las sucesivas pruebas o el tratamiento-para reducir el riesgo de la enfermedad en estudio o de sus complicaciones (25,26). La infección por el VHC cumple con todos los criterios exigibles de un programa de cribado (27,28), de acuerdo con los criterios elaborados por nuestro Ministerio de Sanidad (29) hace aproximadamente una década y que dividiremos en tres categorías:…”

Section: Cribado Del Vhcunclassified

“…Conocemos con detalle la historia natural de la enfermedad y sabemos que un tratamiento adecuado evita la progresión a estadios avanzados e impide la transmisión de la infección. El tratamiento consigue un beneficio individual sobre la propia enfermedad hepática, disminuye la mortalidad de cualquier causa (23), mejora la calidad de vida y evita el desarrollo de manifestaciones extrahepáticas (24,25); en los casos con fibrosis avanzada previene las complicaciones de la cirrosis (20), y en pacientes en lista de espera de trasplante hepático incluso puede suponer evitar el procedimiento (26). Además, produce diferentes beneficios colectivos, como la reducción de nuevas infecciones o el incremento de la facilidad en el acceso al trasplante hepático de otros pacientes.…”

Section: Introductionunclassified